A molecular switch in breast cancer cells reprograms the genetic production line towards tumor growth and stress resistance.
Starting in 2026, NIBRT training will be piloted at Heartland BioWorks’ Indianapolis headquarters with hands-on training beginning in 2027.
Johnson & Johnson has agreed to acquire Halda Therapeutics for $3.05 billion cash, in a deal designed to expand the buyer’s cancer pipeline with Halda’s precision oncology candidates, led by a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback